Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Gynecologic Oncology
•
Cervical Cancer
Do you perform pap smears as part of surveillance of patients with a history of cervical or vaginal cancers who had radiation as part of their treatment?
Related Questions
Would you offer post operative radiation for a patient who had findings of lymphovascular invasion on salvage resection of a recurrent obturator node after definitive chemoradiation for cervical cancer?
Would you ever consider pelvic exenteration followed by SBRT for a patient with recurrent cervical cancer (s/p chemoRT) who has disease only in the central pelvis and in a single hilar lymph node?
In patients treated with the KEYNOTE A-18 regimen who later recur, would you rechallenge with immunotherapy again?
In patients getting concurrent chemo-immunotherapy for locally advanced cervix cancer, would you hold immunotherapy during the 2.5-3 weeks of brachytherapy?
How would you utilize brachytherapy boost in addition to EBRT for HPV-dependent invasive squamous cell carcinoma present as a large pelvic side wall mass, presumed to be of cervix primary, albeit the negative biopsies of the cervix?
Between KEYNOTE A-18 and INTERLACE, for which patients would you recommend using one protocol over another?
What are some considerations for planning T&O brachytherapy in a patient with bilateral hip replacements, where it is difficult to delineate disease on MRI and even surrounding structures on CT?
Do you have concerns about the validity of the INTERLACE data, considering the long study recruitment period (10 years) and evolution of radiation techniques that have occurred during that time frame?
How would you manage bulky cervical adenocarcinoma that incompletely responded to primary chemoradiation?
How do you counsel patients about prognosis with FIGO 2018 IIIC cervix cancer managed in the new era of chemoradiation plus immunotherapy?
